Wir sind mit live! Mehr erfahren
WGS-Symbol

GeneDx Holdings

63,61 USD
-6,61
9,41 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
64,85
+1,24
1,95 %
1 Tag
-9,41 %
5 Tage
-5,53 %
1 Monat
-34,71 %
3 Monate
3,11 %
6 Monate
-2,77 %
Seit Jahresbeginn
-51,92 %
1 Jahr
-46,28 %
5 Jahre
-73,77 %
10 Jahre
-80,33 %
 

Profil: GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Mitarbeiter: 1.300

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 5,1 %
Neutral 94,9 %
Negativ 0 %
Neutral
Business Wire
vor 10 Tagen
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026.
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
Neutral
Business Wire
vor 15 Tagen
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Neutral
Business Wire
letzten Monat
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
Positiv
Zacks Investment Research
letzten Monat
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
3 Promising Genomics Stocks in the Spotlight in 2026
Neutral
Business Wire
letzten Monat
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Positiv
Benzinga
letzten Monat
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market's current top-10 short-interest list, per Benzinga Pro data.
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Neutral
Business Wire
letzten Monat
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
Positiv
Zacks Investment Research
letzten Monat
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
Positiv
Seeking Alpha
vor 2 Monaten
GeneDx: Why I Think The Worst Is Behind The Business
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
GeneDx: Why I Think The Worst Is Behind The Business
Neutral
Business Wire
vor 2 Monaten
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
Kursdiagramme mit Lightweight Charts™ umgesetzt